U.S. stock futures were mixed but mostly steady late Thursday as investors weighed escalating tensions in the Strait of Hormuz and higher oil prices ahead of Friday’s key jobs report.As of 9.30 p.m. ET, Nasdaq 100 futures were up 0.1%, while S&P 500 futures were down by 0.05%. Dow futures were down…
Shares of Iovance Biotherapeutics Inc. (IOVA) soared 34% on Thursday to their highest levels in over 18 months, after the biotech firm reported record second-quarter revenue that beat Wall Street expectations, driven by strong demand for its cancer therapy Amtagvi.IOVA shares appear set to clock th…
Record Q2 revenue and margin were driven by robust Amtagvi demand, expanding ATC network, and operational efficiencies. Pipeline advanced with key regulatory milestones and international approvals, while strong cash reserves support ongoing growth and R&D.Based on Iovance Biotherapeutics, Inc. [IOV…
IOVANCE BIOTHERAPEUTICS, INC. reported second-quarter 2026 results with revenue of $99.3M, a narrowed net loss of $47.3M versus a $111.7M loss in the prior-year quarter, and diluted EPS of $(0.11), reflecting improved performance driven by commercial growth.Financial HighlightsBusiness HighlightsOr…
